title: Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
abstract: Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy. A potent graft-versus-myeloma (GVM) effect can be induced against MM after allogeneic stem cell transplantation (allo-SCT). In all, 31 MM patients received thalidomide as a salvage therapy after progression following allo-SCT. The median maximum daily dose of thalidomide was 200 mg (range, 50-600). Thalidomide had to be discontinued in six patients (19%) because of toxicity. In all, nine patients (29%; 95% CI, 13-45) achieved an objective response with thalidomide therapy (six partial and three very good partial responses, VGPR). Five patients developed graft-versus-host disease (GVHD) after thalidomide therapy, including the three patients achieving a VGPR. These data demonstrate that thalidomide is potentially effective in MM patients failing allo-SCT.
authors.affiliation: Unité de Transplantation et de Thérapie Cellulaire (UTTC), Institut Paoli-Calmettes, Marseille, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: C E
authors.initials: CE
authors.lastname: Bulabois
authors.forename: F
authors.initials: F
authors.lastname: Garban
authors.forename: N
authors.initials: N
authors.lastname: Gratecos
authors.forename: B
authors.initials: B
authors.lastname: Rio
authors.forename: J P
authors.initials: JP
authors.lastname: Vernant
authors.forename: J J
authors.initials: JJ
authors.lastname: Sotto
authors.forename: J Y
authors.initials: JY
authors.lastname: Cahn
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: J P
authors.initials: JP
authors.lastname: Jouet
authors.forename: T
authors.initials: T
authors.lastname: Facon
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
mesh_terms: D000328:Adult; D005260:Female; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide